[go: up one dir, main page]

UY34295A - Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida - Google Patents

Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida

Info

Publication number
UY34295A
UY34295A UY0001034295A UY34295A UY34295A UY 34295 A UY34295 A UY 34295A UY 0001034295 A UY0001034295 A UY 0001034295A UY 34295 A UY34295 A UY 34295A UY 34295 A UY34295 A UY 34295A
Authority
UY
Uruguay
Prior art keywords
ndimetilaminometil
ilcarbonilamino
benzamida
etoxi
benzofuran
Prior art date
Application number
UY0001034295A
Other languages
English (en)
Inventor
Anne Jacquet-Bescond
Kloos Ioana
Chenel Marylore
Robert Renata
Balasubramanian Sriram
Stephane Depil
Sylvain Fouliard
Original Assignee
Servier Lab
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Pharmacyclics Inc filed Critical Servier Lab
Publication of UY34295A publication Critical patent/UY34295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida de fórmula I,o de una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable, solo o en asociación con un tratamiento de cirugía, de quimioterapia, de hormonoterapia o con radioterapia para su utilización en el tratamiento del cáncer, caracterizada porque se administra durante 4 días consecutivos, estando seguido este periodo de 3 díasconsecutivos sin ninguna administración del compuesto de fórmula (I), con la salvedad de que el tratamiento de quimioterapia no es el FOLFOX. Medicamentos.
UY0001034295A 2011-09-08 2012-08-28 Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida UY34295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161573585P 2011-09-08 2011-09-08
FR1102727 2011-09-08

Publications (1)

Publication Number Publication Date
UY34295A true UY34295A (es) 2013-04-30

Family

ID=47830027

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034295A UY34295A (es) 2011-09-08 2012-08-28 Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida

Country Status (17)

Country Link
US (2) US8883199B2 (es)
EP (1) EP2753322B1 (es)
JP (1) JP6014142B2 (es)
KR (1) KR20140073521A (es)
CN (1) CN103889409A (es)
AR (1) AR087803A1 (es)
AU (2) AU2012306122A1 (es)
CA (1) CA2847011A1 (es)
HK (1) HK1201150A1 (es)
MX (1) MX2014002663A (es)
RU (1) RU2600793C2 (es)
SG (2) SG11201400120UA (es)
TW (1) TWI544920B (es)
UA (1) UA113634C2 (es)
UY (1) UY34295A (es)
WO (1) WO2013034863A1 (es)
ZA (1) ZA201401710B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328819T3 (es) 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
EP2626067A1 (en) * 2006-12-26 2013-08-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US7838234B2 (en) * 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2755648B1 (en) 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AR097204A1 (es) 2013-08-02 2016-02-24 Pharmacyclics Inc Métodos de tratamiento de tumores sólidos
KR101684854B1 (ko) * 2016-06-13 2016-12-09 아이오틴 주식회사 보호자 알림기능을 이용한 휴대용 스마트약통 및 이를 포함하는 복용시간 알림시스템
CN114146181B (zh) * 2021-10-29 2022-09-09 徐诺药业(南京)有限公司 含Pan-HDAC和免疫检查点抑制剂的组合及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535267A (en) * 2002-03-28 2006-03-31 Tanabe Seiyaku Co Benzofuran derivatives as inhibitors of blood coagulation factor X
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
ES2328819T3 (es) * 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
AU2006238877A1 (en) * 2005-04-21 2006-11-02 Alza Corporation Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Also Published As

Publication number Publication date
AU2012306122A1 (en) 2014-03-13
EP2753322B1 (fr) 2016-08-03
CA2847011A1 (fr) 2013-03-14
HK1201150A1 (en) 2015-08-28
AR087803A1 (es) 2014-04-16
UA113634C2 (uk) 2017-02-27
KR20140073521A (ko) 2014-06-16
WO2013034863A1 (fr) 2013-03-14
US20150024040A1 (en) 2015-01-22
TWI544920B (zh) 2016-08-11
AU2016202594A1 (en) 2016-05-19
US8883199B2 (en) 2014-11-11
JP2014526457A (ja) 2014-10-06
RU2600793C2 (ru) 2016-10-27
NZ622112A (en) 2016-07-29
AU2016202594B2 (en) 2017-09-14
EP2753322A1 (fr) 2014-07-16
CN103889409A (zh) 2014-06-25
RU2014113399A (ru) 2015-10-20
JP6014142B2 (ja) 2016-10-25
MX2014002663A (es) 2014-08-29
US20130064880A1 (en) 2013-03-14
SG11201400120UA (en) 2014-09-26
ZA201401710B (en) 2015-01-28
TW201313228A (zh) 2013-04-01
SG10201505619QA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
UY34295A (es) Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
UY34365A (es) Compuestos heterociclicos
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34472A (es) Derivados modificados de 4-fenil-piridina
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34523A (es) Derivados de betulina
CR20130539A (es) Triazolopiridinas
CR20120295A (es) Triazolopiridinas
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
HUE056365T2 (hu) 2-(2,4,5-Helyettesített-anilino)pirimidin származékok
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34251A (es) derivados de isoxazolina como compuestos insecticidas.
UY34654A (es) Inhibidores de la beta-secretasa
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
UY34057A (es) Inhibidores del virus de la hepatitis c
UY34013A (es) ?compuestos de cromenona con actividad anti-tumoral?.
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
CR20120637A (es) Triazolopiridinas sustituidas
UY33642A (es) Formula mejorada de herbicida
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
UY34469A (es) Composicion herbicida
UY33976A (es) Derivados de pirazolo-pirimidina.
UY34329A (es) Compuestos de triazolopiridina
UY34407A (es) Nuevos moduladores de trpv3

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211015